Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.508
-0.001 (-0.26%)
Nov 21, 2024, 12:53 PM EST - Market open
Company Description
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States.
Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics, Inc.
Country | United States |
Founded | 2016 |
IPO Date | Jul 13, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Shalabh Gupta |
Contact Details
Address: 4300 El Camino Real, Suite 210 Los Altos, California 94022 United States | |
Phone | 650 351 4495 |
Website | unicycive.com |
Stock Details
Ticker Symbol | UNCY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001766140 |
CUSIP Number | 90466Y103 |
ISIN Number | US90466Y1038 |
Employer ID | 81-3638692 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer and President |
Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
John W. Townsend CPA | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 20, 2024 | EFFECT | Notice of Effectiveness |
Nov 14, 2024 | EFFECT | Notice of Effectiveness |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SCHEDULE 13G/A | Filing |
Nov 14, 2024 | SCHEDULE 13G/A | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |